Smith & Nephew plc (LON:SN) Stock Has Average Target Price of GBX 1,293.33 According to Analysts

by · The Markets Daily

Smith & Nephew plc (LON:SN – Get Free Report) has been given a consensus rating of “Hold” by the nine research firms that are covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is GBX 1,293.33.

Several research firms have recently weighed in on SN. Shore Capital Group reaffirmed a “buy” rating and set a GBX 1,000 target price on shares of Smith & Nephew in a report on Tuesday, July 21st. Jefferies Financial Group reiterated a “buy” rating and set a GBX 1,500 target price on shares of Smith & Nephew in a research report on Friday, September 4th. Berenberg Bank dropped their target price on shares of Smith & Nephew from GBX 1,300 to GBX 1,250 and set a “hold” rating on the stock in a research report on Friday, August 14th. JPMorgan Chase & Co. decreased their target price on Smith & Nephew from GBX 1,438 to GBX 1,290 and set a “neutral” rating on the stock in a research report on Thursday, August 6th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a GBX 1,250 target price on shares of Smith & Nephew in a report on Tuesday, September 15th.

Get Our Latest Report on SN

Smith & Nephew Price Performance

SN stock opened at GBX 1,084.50 on Friday. The company has a 50 day simple moving average of GBX 1,048.24 and a two-hundred day simple moving average of GBX 1,115.64. The stock has a market cap of £11.89 billion, a P/E ratio of 39.05, a P/E/G ratio of 0.46 and a beta of 0.69. The company has a debt-to-equity ratio of 73.07, a current ratio of 2.14 and a quick ratio of 0.84.

About Smith & Nephew

(Get Free Report)

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.

Featured Articles